Ocera Therapeutics Inc

Ocera Therapeutics — Investor Presentation (March 2015)

29 slides from Ocera Therapeutics's investor presentation, Mar 2, 2015

  1. Slide 1: Bringing Innovative Therapeutics for People with Orphan Liver Disease

    Bringing Innovative Therapeutics for People with Orphan Liver Disease MARCH 2015 NASDAQ: OCRX

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, all stateme

  3. Slide 3: "When the liver fails, the brain fails."

    “When the liver fails, the brain fails.” Professor Rajiv Jalan; University College London

  4. Slide 4: Building a Liver Disease Medicines Company

    Building a Liver Disease Medicines Company Clinical-stage development for treatment of Hepatic Encephalopathy IV and oral formulations Strong patent coverage Differentiated Product Candidate: OCR-002 STOP-HE Phase 2b interim analysis Completion of Phase 2b enrollment Results of two investigator-spon

  5. Slide 5: Liver Disease: Caused by Many Conditions

    Liver Disease: Caused by Many Conditions Chronic Liver Disease in U.S. 8 Million Alcohol Use Hepatitis Obesity Drug Exposure NASH / Fatty Liver Diabetes Autoimmune Diseases

  6. Slide 6: Liver Disease Causes Hepatic Encephalopathy (HE)

    Liver Disease Causes Hepatic Encephalopathy (HE) 1 Million Liver Cirrhosis 40 - 60% At Risk for HE ~120,000 Admitted to Hospital Annually with Acute HE

  7. Slide 7: Hepatic Encephalopathy: Neurocognitive Disorder in Serious Liver Disease

    Hepatic Encephalopathy: Neurocognitive Disorder in Serious Liver Disease Blood Stream Ammonia Gut Acute on Chronic Liver Disease Acute Liver Failure Elevated ammonia levels drive HE Personality Disorientation Stupor Coma Death Changes Impaired Motor Skills Intra-cranial Coma Death hypertension

  8. Slide 8: Growing Body of Evidence Supports Correlation Between Blood Ammonia Levels and HE

    Growing Body of Evidence Supports Correlation Between Blood Ammonia Levels and HE Severity of HE Symptoms Ammonia Intracranial Pressure Ammonia Ammonia measurements shown to correlate (p < 0.001) with severity of HE Independent, prospective study of 121 hospitalized patients with chronic cirrhosis1

  9. Slide 9: Treatment of Acute HE: Need for New Therapy

    Treatment of Acute HE: Need for New Therapy Standard of care in acute and chronic HE Laxative, indirectly reduces ammonia by flushing gut Difficult administration and diarrhea Poor patient compliance Lactulose Non-absorbed antibiotic approved for prevention of HE Limited evidence of efficacy in acut

  10. Slide 10: Increasing HE Hospitalizations in U.S.

    Increasing HE Hospitalizations in U.S. (000s) Source: HCUP 2012 and independent market research 65% GROWTH from 2002-2012 120k patients account for 175k hospitalizations per year Source: HCUP 2012 and independent market research

  11. Slide 11: Payment Amount on HE Inpatient Claims

    PAYMENT AMOUNT ON HE INPATIENT CLAIMS (2011)1 1 2011 CMS Medicare data and other commercial payors; N = 73,467 2 Ocera commissioned market research showing that 80% of the 106 hospital surveyed would support OCR-002 at $1,300 per 24 hours if it reduces ICU stay Median Mean CMS $10,111 $15,056 Other

  12. Slide 12: Significant Opportunity to Reduce Length of Stay

    60% HE Patients Hospitalized for > 5 Days Significant Opportunity to Reduce Length of Stay: OCR-002 >14 days 15% 5-14 days 45% 1-4 days 40% PATIENT HOSPITAL STAY DISTRIBUTION Source: 2011 CMS Medicare data; N=74,653 total claims

  13. Slide 13: The Demons of the Disease

    The Demons of the Disease Progressive, episodic disorder with high mortality rate Majority of affected individuals eventually lose independence; significant impact on quality of life Advanced HE marked by delirium, overactive reflexes and coma1 Hospitalized patients can be very sick, stuporous, intu

  14. Slide 14: Hospitalized HE Patients Need Rapid Treatment

    Hospitalized HE Patients Need Rapid Treatment OCR-002 IV Ammonia scavenger Ammonia lowering observed in cirrhotic patients IV formulation for immediate, systemic action Well-tolerated in clinical trials to date

  15. Slide 15: OCR-002 Dual Mechanism of Action

    Phenylacetate Ornithine Non-Toxic Carrier of Ammonia, Contributes to Muscle Building OCR-002 Dual Mechanism of Action Clears Ammonia When the Liver Cannot Ornithine “Pushes” Ammonia into Blood Stream PAA “Pulls” It into the Urine Animal and Early Human Data Validate Mechanism Converted to Glutamate

  16. Slide 16: Early Human Validation Shows Ammonia Reduction

    Early Human Validation Shows Ammonia Reduction 3rd-party study showed that combination of Ornithine (LOLA) and Phenylacetate (Phenylbutyrate) Lowers Ammonia More Than Either Alone 8 patients with cirrhosis and hyperammonemia; N=2/arm 1 “L-Ornithine Phenylacetate (OP): a Novel Treatment for Hyperammo

  17. Slide 17: OCR-002 IV Well-Tolerated in Phase 1 Trial

    OCR-002 IV Well-Tolerated in Phase 1 Trial No Serious Adverse Events; No Deaths or Discontinuations PK Profile Established Safety Margins Identified Stable Cirrhotic Patients, Ammonia Levels not Measured Maximum Dose Tested 40g per 24 hours Most frequent dose related toxicities at 40g included dizzi

  18. Slide 18: 2015 Phase Trials of OCR-002

    2015 Phase 2 Trials of OCR-002 Phase 2b Trial in Acute HE Phase 2a Trial for Acute Liver Failure/Injury Phase 2a Trial in Cirrhosis and Upper GI Bleed IN PROGRESS COMPLETE

  19. Slide 19: STOP-HE Phase 2b Ocera Study: OCR-002 IV for Acute HE

    STOP-HE Phase 2b Ocera Study: OCR-002 IV for Acute HE Efficacy RANDOMIZED DOUBLE-BLIND TRIAL OCR-002 20g** per 24 hours + Standard of Care Placebo + Standard of Care HOSPITALIZED CIRRHOTICS Key Inclusion West Haven* Score > 2 Ammonia >ULN Key Exclusion Kidney failure/dialysis Life expectancy < 2 wee

  20. Slide 20: Meaningful Clinical Improvement as Scored by Modified West Haven Scale

    Meaningful Clinical Improvement as Scored by Modified Version of West Haven Scale 4 3 2 1 0 --- Hospitalization --- Comatose Stuporous Disoriented Difficult to Arouse Asterixis Mild Confusion Normal Grade / Symptoms Meaningful Clinical Improvement 4 to 2 or lower 3 to 2 or lower 2 to 1 or lower Mode

  21. Slide 21: UGIB Phase 2a Investigator Trial - Completed

    UGIB Phase 2a Investigator Trial - Completed OCR-002 IV in Cirrhosis & Upper GI Bleed (UGIB) PART B: 10g PER 24 HOURS PLACEBO-CONTROLLED(N=38) OCR-002 treatment arm vs. placebo: Greater absolute and relative reductions in median plasma ammonia at 12 hours after baseline More rapid hourly decline in

  22. Slide 22: UGIB Investigator Study and Ocera STOP-HE Studies Compared

    UGIB Investigator Study and Ocera STOP-HE Studies Compared UGIB Phase 2a (Part B) STOP-HE Phase 2b Patient Population cirrhotic plus UGIB cirrhotic plus HE Investigative Sites 2 (Spain) ~100 (US and EU) N Randomized 38 ~140 expected OCR-002 Dose 10g 20g, may be adjusted to 15 or 10g based on liver i

  23. Slide 23: STOP-ALF Phase 2a NIH-Sponsored Study in Acute Liver Failure

    STOP-ALF Phase 2a NIH-Sponsored Study: OCR-002 IV in Acute Liver Failure ACUTE LIVER FAILURE PATIENTS: ULTRA ORPHAN POPULATION (2,000/YR) Often young, otherwise healthy Acetaminophen overdose and other acute liver shocks ~40-65% spontaneous recovery1,2 ~30% mortality1,2 ~8-30% require transplantatio

  24. Slide 24: OCR-002: Continuity of Care for HE Patients

    OCR-002: Continuity of Care for HE Patients OCR-002 CANDIDATES Unmet Medical Need Optimal Formulation for Acute Patient Population Treatment of Hospitalized HE All IV ORAL Maintenance of Chronic HE Remission All Continuity of Care post IV Non-Antibiotic Alternative to rifaximin, or combined with rif

  25. Slide 25: Significant Opportunity for IV and Oral OCR-002

    Significant Opportunity for IV and Oral OCR-002 ~175K Annual Hospitalizations1 Potentially Favorable Reimbursement Sole Standard of Care Protocol in Most Institutions ORAL IV Continuity of Care Following Treatment with IV Can be Combined with Rifaximin 1 Company estimates based on 2012 data Source:

  26. Slide 26: Strong Patent Coverage of OCR-002

    Strong Patent Coverage of OCR-002 2030 2025 2031 2025 Broad Composition Claims Granted/Allowed in Europe, Japan, China and Several Other Countries Specific Drug Substance Granted/Allowed in U.S., China, and Several Other Countries; Pending Worldwide Treatment of Hepatic Encephalopathy Granted in U.S

  27. Slide 27: Executing Against our Clinical Objectives

    OCR-002 (IV) – STOP-HE Acute HE Initiated Phase 2b trial DMC recommendation from interim analysis (Q1-2015) Enrollment completion (YE-2015) OCR-002 (IV) – Externally Sponsored Phase 2a Readouts Cirrhosis and GI bleed (Spain) STOP-ALF Acute Liver Failure (NIH) OCR-002 (Oral) Commenced formulation dev

  28. Slide 28: Team with Deep Experience

    Team with Deep Experience Linda S. Grais, MD, JD President & Chief Executive Officer Gaurav Aggarwal, MD Chief Business Officer Michael Byrnes, MBA Chief Financial Officer Rajiv Patni, MD Chief Development Officer

  29. Slide 29: Building a Liver Disease Medicines Company

    Building a Liver Disease Medicines Company Clinical-stage development for treatment of Hepatic Encephalopathy IV and oral formulations Strong patent coverage Differentiated Product Candidate: OCR-002 STOP-HE Phase 2b interim analysis Completion of Phase 2b enrollment Results of two investigator-spon

Ocera Therapeutics — Investor Presentation (March 2015) on 6ix